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Expression of beta-2-microglobulin by nasopharyngeal carcinoma
W. Shiu, S.F. Leung, W.T. Leung, S. Ho & M. Tao
Department ofClinical Oncology, Chinese University ofHong Kong at Prince of Wales Hospital, Hong Kong.
Summary Serum beta-2-microglobulin (02M) levels of 274 Chinese patients with different stages of
nasopharyngeal carcinoma at presentation and that of 35 patients who developed distant metastases post-
treatment were assayed. P2M level was found to increase with advancing stage of disease, with statistically
significant differences among early-stage, advanced-stage, and metastatic disease. Elevated pre-treatment P2M
levels were expressed more frequently by tumours with lower degree of histological differentiation. The
sensitivity of serum P2M for diagnosis of nasopharyngeal carcinoma, however, is low.
Beta-2-microglobulin (132M) is a protein of low molecular
weight (11,800 daltons). It was first isolated from urine in
patients with Wilson's disease in 1968 (Berggard et al., 1968).
It is found on the cell membrane of all nucleated cells and
platelets and it forms the light chain moiety of the major
histocompatibility antigens. Cell membrane turnover is the
principle source of P2M in blood, plasma and body fluids
(Cresswell et al., 1974; Forman, 1982). Elevated serum levels
has been found to be associated with increasing age, renal
impairment (Bailey et al., 1978) and a variety ofmalignancies
and appears to be a reflection of tumour load in patients
with lymphoma (Anderson et al., 1983; Hagberg et al., 1983),
myeloma (Child et al., 1983; Norfolk et al., 1980; Alexanian
et al., 1985), lung cancer (Schweiger & Tocsanyi, 1978), breast
cancer (Teasdal et al., 1977; Rashid et al., 1980), and
squamous cell carcinoma of the head and neck (Wennerberg
et al., 1984). Nasopharyngeal carcinoma (NPC) is a
commonly-occurring tumour in Hong Kong. The value of
P2M as a diagnostic marker for NPC and its correlation with
tumour load is the subject of the present investigation.
Method and materials
Serum samples of 73 healthy volunteers were used to estab-
lish a normal reference range for P2M. Serum samples of 274
Chinese patients with NPC were collected at presentation
and/or at follow-up and stored at -70° until assayed. The
characteristics of the patients are shown in Table I, and the
distribution of histologies in Table II. Serum P2M level was
measured by radioimmunoassay (Pharmacia beta-2-micro,
RIA, Sweden). Serum creatinine level was routinely checked
to exclude renal impairment. It was found to be normal for
all the patients at the time of sample collection. The Student
t-test was used for statistical analysis.
Results
Normal reference range ofP2M
A reference range of serum P2M levels in normal subjects was
established at 0.96-1.88 mg 1-l (mean +/- 2 S.D.). For the
purpose of the present study, an arbitrary cut-off value of
2 mg 1' was adopted (Figure 1).
Serum P2M levels and staging ofNPC
There was a trend for progressive increase in mean serum
P2M levels and in the percentage of patients with elevated
P2M levels with advancing stage of disease (Figure 1 and
Table I). By grouping patients into an 'early-stage' group, an
'advanced-stage' group and a 'metastatic' group, significant
differences in mean levels and percentages of patients with
elevated levels were obtained. The greatest difference in mean
levels was found between metastatic NPC and other stages
combined (p<0.001).
Sensitivity ofP2Mfor diagnosis ofNPC
Using a reference upper normal limit of 2mgl 1, the sen-
sitivity of serum P2M for detection of NPC for the whole
group of NPC patients is 37%, the sensitivities for the sub-
groups are: Stage I 23%, Stage II 17%, Stage III 25%, Stage
IV 36%, metastatic disease 96%.
Serum 1B 2M levels andhistological differentiation
Table II shows that the percentage of patients with elevated
pre-treatment levels of P2M increased with lower degree of
histological differentiation, though the difference has not
reached statistically significant levels.
Serum 132M levels and site ofdistant metastatic disease
The elevation in P2M level was expressed by metastases at a
variety of sites including bone, lung, liver, bone-marrow,
breast and skin, and thus was not dependent on the site of
distant metastases.
Discussion
The mean serum P2M levels of the 73 Chinese healthy nor-
mals is very close to that reported by Lai et al. (Lai et al.,
1986) and is significantly different from that of the NPC
population. However, serum 132M appears to have little diag-
nostic value in view of the very low sensitivity of the test and
availability of more sensitive serological markers such as the
IgA titre to the viral capsid antigen of Epstein-Barr virus
(Ho et al., 1976). Although P2M has a high sensitivity in
metastatic disease, the clinical relevance in this situation is
limited.
The expression of elevated P2M levels was found to be
related to the histological differentiation in NPC. This may
be due to more active cellular proliferation in tumours with
poorer histological differentiation. Similar findings however
were not evident in non-Hodgkin's lymphoma (Anderson et
al., 1983).
The general increase of mean P2M levels from stage I to IV
and metastatic disease is probably a reflection of increasing
tumour load, although increasing intensities of an immune
response and a direct effect of Epstein-Barr virus infection
are alternative explanations. Stage-dependency of P2M levels
has also been reported in non-Hodgkin's lymphoma (Ander-
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Table I Serum P2M levels in NPC population and control population
P2M conc
Mean Sex ratio mean ± SD P2M range
Population Number age M:F (mg 1-') (mg 1-)
Healthy normal 73 45.3 2.4:1.0 1.42 0.23 0.98- 1.93
NPC Stage I 22 48.7 2.1:1.0 1.62 0.40 0.99- 2.40
NPC Stage II 74 45.7 2.5:1.0 1.64 0.42 1.08- 2.79
NPC Stage III 105 45.9 3.2:1.0 1.75 0.66 0.89- 5.00
NPC Stage IV 58 47.5 5.4:1.0 1.95 0.66 1.00- 4.35
NPC metastatica 51 50.2 4.7:1.0 3.64 1.94 1.70-10.70
'Early' NPC 96 1.64 0.41 0.99- 2.79
(Stage I & II
combined)
'Advanced' NPC 162 1.82 0.67 0.89- 5.00
(Stage III & IV
combined)
aComprises 16 patients with distant metastatic disease at presentation (NPC
Stage V) and 35 patients who developed distant metastases after treatment.
Table II Correlation between histological differentiation and
pre-treatment levels of W2M
Histological No. ofpatients % ofpatients with
Stage differentiation insubgroup 32M>2 mgI'
M.D. 3 0(0/3)
P.D. 7 14(1/7)
U 12 33 (4/12)
II M.D. 3 0(0/3)
P.D. 22 9(2/22)
U 45 22(10/45)
III M.D. 4 25 (1/4)
P.D. 37 27(10/37)
U 56 23 (13/56)
IV M.D. 0 0(0/0)
P.D. 20 20(4/20)
U 36 44(16/36)
All M.D. 10 10(1/10)
(Stages I P.D. 86 20(17/86)
toIV) U 149 29(43/149)
M.D. = moderately differentiated squamouscellcarcinoma. P.D. = poorly















son et al., 1983), breast cancer (Teasdal et al., 1977) and
myeloma (Hagberg et al., 1983; Alexanian et al., 1985), and
is thought to be due to increased cell turnover (Karlsson et
al., 1980) and/or augmented immune response by lym-
phocytes to the neoplasm (Forman, 1982; Rashid et al., 1980;
Karlsson et al., 1980; Shuster et al., 1976).
In another study, however, the P2M level was lower in
early and advanced stages than in intermediate stages (Lotz-
niker et al., 1988): the decrease with more advanced stages
was attributed to a weakened immunologic response in
advanced disease. NPC is known to be associated with cer-
tain immunologic alterations in the patient, including lym-
phopenia, reduced T4/T8 lymphocyte subset ratio (Cheng et
al., 1989), impaired cell-mediated immune functions (Chan et
al., 1976), and elevated antibody titres to the Epstein-Barr
virus (Ho et al., 1976). Stage-dependency is not a feature of
most of these immunological alterations except lymphopenia
(Cheng et al., 1989) and the IgA titre to the viral capsid
antigen of Epstein-Barr virus (Henle et al., 1973). There is no
evidence, except on the contrary, to suggest an absolute
increase in the total lymphocyte population or its subset in
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creased immunologic response accounting for increasing P2M
levels in different stages of NPC is unlikely. The association
between NPC and Epstein-Barr virus is well-established and
demonstrable at serological, histopathological and genetic
levels (Ho et al., 1976; Huang et al., 1974; Lung et al., 1990).
Raised P2M levels has also been found in patients with
infectious mononucleosis - an Epstein-Barr virus-related con-
dition - and other herpes virus infections (Lamelin et al.,
1983; Cooper et al., 1984; Norfolk et al., 1987). However,
there is no known common mechanism to account for the
raised levels of P2M in different viral infections. Neither is
there evidence to prove that increased T-cell activation,
which occurs in infectious mononucleosis, occurs in a com
parable manner in NPC. A direct effect of the virus accoun-
ting for increasing P2M levels in advancing stages of NPC is
thus difficult to substantiate.
The segregation of three groups of NPC patients with
significant differences in P2M levels in our study may provide
a basis for staging patients based on tumour burden. It may
assist the selection of subsets of patients with advanced-stage
disease for more aggressive treatment with adjuvant
chemotherapy. The validity of these statements would require
proof of pre-treatment P2M level as an independent prognos-
tic factor, and follow-up assessment of a larger patient
population would be required for this purpose.
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